Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helle Linnebjerg

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Clinical Pharmacokinetics|May 30, 2020
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog<sup>®</sup> (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled TrialHelle Linnebjerg, Qianyi Zhang, Elizabeth LaBell, et al.
Diabetes, Obesity & Metabolism|May 22, 2020
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover studyTim Heise, Helle Linnebjerg, David Coutant, et al.
Clinical Pharmacology in Drug Development|April 28, 2016
Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mLAmparo de la Peña, Mary Seger, Danny Soon, et al.
Clinical Pharmacokinetics|May 30, 2020
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog<sup>®</sup> (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover StudyJennifer Leohr, Mary Anne Dellva, David E Coutant, et al.
Journal of Clinical Pharmacology|August 16, 2005
Effect of exenatide on the steady-state pharmacokinetics of digoxinPrajakti A Kothare, Danny K W Soon, Helle Linnebjerg, et al.
Diabetes Care|August 27, 2015
Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp StudiesHelle Linnebjerg, Eric Chen Quin Lam, Mary E Seger, et al.
JAMA|August 28, 2023
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical TrialStephen J Nicholls, Steven E Nissen, Cynthia Fleming, et al.
Diabetes Technology & Therapeutics|March 23, 2017
Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow MicroperfusionKatrin Tiffner, Beate Boulgaropoulos, Christian Höfferer, et al.
Diabetes, Obesity & Metabolism|February 23, 2026
Characterisation of steady-state pharmacokinetics and glucodynamics of once-weekly insulin efsitora alfa in individuals with type 2 diabetesJennifer Leohr, Oliver Klein, Tim Heise, et al.
JAMA|November 12, 2023
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical TrialSteven E Nissen, Helle Linnebjerg, Xi Shen, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Clinical Pharmacokinetics|May 30, 2020
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog<sup>®</sup> (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled TrialHelle Linnebjerg, Qianyi Zhang, Elizabeth LaBell, et al.
Diabetes, Obesity & Metabolism|May 22, 2020
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover studyTim Heise, Helle Linnebjerg, David Coutant, et al.
Clinical Pharmacology in Drug Development|April 28, 2016
Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mLAmparo de la Peña, Mary Seger, Danny Soon, et al.
Clinical Pharmacokinetics|May 30, 2020
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog<sup>®</sup> (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover StudyJennifer Leohr, Mary Anne Dellva, David E Coutant, et al.
Journal of Clinical Pharmacology|August 16, 2005
Effect of exenatide on the steady-state pharmacokinetics of digoxinPrajakti A Kothare, Danny K W Soon, Helle Linnebjerg, et al.
Diabetes Care|August 27, 2015
Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp StudiesHelle Linnebjerg, Eric Chen Quin Lam, Mary E Seger, et al.
JAMA|August 28, 2023
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical TrialStephen J Nicholls, Steven E Nissen, Cynthia Fleming, et al.
Diabetes Technology & Therapeutics|March 23, 2017
Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow MicroperfusionKatrin Tiffner, Beate Boulgaropoulos, Christian Höfferer, et al.
Diabetes, Obesity & Metabolism|February 23, 2026
Characterisation of steady-state pharmacokinetics and glucodynamics of once-weekly insulin efsitora alfa in individuals with type 2 diabetesJennifer Leohr, Oliver Klein, Tim Heise, et al.
JAMA|November 12, 2023
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical TrialSteven E Nissen, Helle Linnebjerg, Xi Shen, et al.
Pageof 4